1. BioSyent declares a quarterly dividend of $0.05 per share. 2. Dividend payable on September 15, 2025, to eligible shareholders. 3. Company maintains a consistent dividend from the previous quarter. 4. BioSyent focuses on acquiring innovative pharmaceutical products. 5. It has a total of 11,260,794 common shares outstanding.
The consistent dividend may enhance investor confidence, possibly driving stock prices up. Similar companies usually see stock appreciation following dividend declarations, notably in stable sectors.
The dividend payment reflects strong financial health, which may attract value investors. As BioSyent is focused on innovative healthcare solutions, this development increases its appeal in the competitive pharmaceutical market.
Investors may respond positively to the dividend announcement quickly, but potential long-term growth relies on product acquisition. Past trends indicate immediate after announcements lead to short-lived rallies.
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (("BioSyent", "the Company", TSXV:RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
As of the date of this press release, the Company has 11,260,794 common shares outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
